Ипрожин

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ипрожин

Property Description
Active ingredient Progesterone (INN)
Form Capsules (for oral or vaginal use), injection solution
Pharmacological class Progestogen, Steroid Hormone
Common use Hormonal balance and reproductive support
Origin Chemically identical to the natural human hormone

What Type of Medication is Ипрожин (Progesterone)?

Ипрожин is a medicinal product containing Progesterone, which is broadly classified as both a Progestogen and an Endogenous Steroid Hormone. The product is a single-ingredient preparation designed to supplement or regulate the body's supply of this crucial hormone. Its identity as Progesterone is clinically recognized for its essential role in maintaining the integrity of the female reproductive system. Progesterone is categorized within the therapeutic group of sex hormones.

Composition and Origin: Is the Progesterone in Ипрожин Natural?

The active compound in Ипрожин is Progesterone that is chemically identical to the hormone produced naturally by the human body. This unique formulation is considered bioidentical and is not a synthetic derivative. To enable effective use via various routes of administration, the preparation utilizes Micronized Progesterone, a finely processed form. This micronized structure is a key differentiating feature that enhances the hormone's bioavailability. The formulation is available as capsules and an injection solution, which commonly contain the micronized substance suspended in a lipophilic oil base.

The General Purpose of This Progestogen

The general purpose of the medication is to support and regulate key physiological processes that rely on adequate progesterone levels. Progesterone is recognized as a key component of the menstrual cycle and pregnancy. This indicates that the medication's primary function is to contribute to hormonal balance regulation and induce the necessary secretory changes in the endometrium (uterine lining). This action is fundamental for maintaining the stability required for specific reproductive functions, such as supporting the lining of the uterus.

Regulatory References

  1. Progesterone (NIH StatPearls)
  2. PMC6281289

What side effects are possible with Ипрожин?

Possible Side Effects and Safety Information

The safety profile of progesterone (Ипрожин) is formally established by regulatory documents, classifying potential adverse reactions by both frequency and the body system affected. These classifications are critical for understanding the official regulatory description of the medicine's risk profile.

Adverse Reaction Classification

Side effects are grouped into categories such as Common (1/100 to < 1/10) and Uncommon, based on the frequency reported in clinical data. Common effects often include disturbances of the Nervous System (e.g., somnolence, dizziness, headache) and the Gastrointestinal System (e.g., nausea, abdominal pain, diarrhea). Other frequently documented effects are related to the Reproductive System and Breast Disorders, such as breast tenderness and altered menstrual cycles.

Documented Serious Safety Concerns

The regulatory label explicitly documents the potential for Serious Adverse Reactions, which include the risk of Arterial and Venous Thromboembolism (such as Deep Vein Thrombosis, Pulmonary Embolism, Stroke, and Myocardial Infarction). The risk of severe Cholestatic Jaundice is also a documented safety consideration. Furthermore, in older adults (aged 65 and over), an increased risk of probable dementia has been reported with combination estrogen-progestin therapy.

Official Safety Restrictions

Specific patient conditions are identified in official labeling as contraindications (absolute restrictions on use). These include a history of thromboembolic disorders, known or suspected progestin-dependent malignant tumors (such as breast cancer), and severe hepatic impairment or acute liver disease. The profile also notes that some effects, such as drowsiness, may be transient and more pronounced during the initial phase of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory guidance defines overdose scenarios for Progesterone based on documented clinical manifestations and specific mandates for seeking emergency care.

Feature Official Regulatory Statement
Documented Overdose Manifestations Clinical signs of overexposure frequently documented in official regulatory sources include central nervous system (CNS) effects such as somnolence, drowsiness, dizziness, and fatigue.
Emergency-Response Statements Management is strictly symptomatic and supportive. Following accidental overingestion of multiple capsules, the required action is to discontinue the medication.
Immediate Medical Help Required It is mandatory to seek immediate medical attention and contact emergency services if severe symptoms occur, including collapse, seizure, or difficulty breathing [MedlinePlus Drug Information].
Antidote Information No specific antidote is known for Progesterone overdose.

In all cases of suspected overdose, a healthcare professional or poison control center must be contacted at once for guidance. The profile is structured to inform users of the officially documented symptoms and the precise conditions under which urgent medical intervention is required, without providing individual clinical advice.

Therapeutic Uses of Ипрожин

The therapeutic scope of Ипрожин, which contains the hormone progesterone, is commonly used to help with conditions that involve hormonal deficits and symptoms related to systemic imbalance. The medication may be part of symptomatic management across key gynecological and obstetric domains.

This medication is primarily relevant for addressing conditions like secondary amenorrhea (absent periods) and abnormal uterine bleeding, supporting the luteal phase during fertility treatments, offering support in cases of recurrent pregnancy loss, and contributing to endometrial support when postmenopausal women receive estrogen therapy.

The general benefit provided involves supportive symptomatic relief across conditions requiring assistance with uterine stability and functional processes dependent on adequate progesterone levels. As a result,

“It may assist in addressing symptoms that interfere with daily functioning, such as sleep disturbances, and supports general well-being during symptomatic phases.”


Quick Fact: Relief for Hormonal Fluctuation
Ипрожин is relevant for managing systemic symptoms like hot flashes and night sweats that cluster during the menopausal transition, helping to support functional stability and general comfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Ипрожин (Progesterone)

Official regulatory documents define strict criteria for who can and cannot use this medicine. Use is primarily established for adult women of reproductive age and postmenopausal women receiving Hormone Replacement Therapy (HRT) for endometrial protection. Use is generally not recommended in children, adolescents before menarche, or during breastfeeding.

Absolute Contraindications (Must Not Use)

Contraindicating Condition Regulatory Status
Active or recent thromboembolic disease (e.g., DVT, PE) Contraindicated
Known or suspected hormone-dependent cancer (e.g., breast cancer) Contraindicated
Severe hepatic impairment or active liver disease Contraindicated
Undiagnosed abnormal genital bleeding Contraindicated

Use requires close medical supervision and caution for patients with a history of depression, migraine, epilepsy, or conditions affected by fluid retention. The medicine is permitted only for specific indications, such as luteal support, during the first trimester of pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Progesterone (Ипрожин) is primarily defined by the body's metabolic processes and the route of administration, as documented in official government labeling. The most significant pharmacokinetic interactions involve the Cytochrome P450 3A4 (CYP3A4) enzyme system in the liver.


Documented Pharmacokinetic Interactions

Substance Category Interaction Effect (Regulatory Statement)
Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Grapefruit juice) Documented to increase the bioavailability and plasma concentration of progesterone, due to reduced metabolism.
CYP3A4 Inducers (e.g., Rifampicin, St. John’s wort) Documented to decrease the level and effect of progesterone by accelerating its clearance.

Other Administration and Substance Constraints

  • Food Effect: The ingestion of a high-fat meal with the oral capsule formulation is documented to increase the absorption (AUC and Cmax) of progesterone.
  • Local Interference: For vaginal formulations, the concomitant use of other vaginal products is officially not recommended as it may physically alter the release and subsequent absorption of the drug.
  • Specific Drug Exposure: Progesterone is documented to increase the plasma concentrations of co-administered drugs such as the immunosuppressant Ciclosporin and certain central nervous system agents.
  • Population Restriction: The drug is officially contraindicated in patients with hepatic impairment or liver disease due to the potential for significantly increased drug exposure (reduced clearance).

Mechanism of Action

Nuclear and Membrane Receptor Agonism

The core mechanism involves Ипрожин acting as a direct agonist at the Nuclear Progesterone Receptors ( PRs) and Membrane Progesterone Receptors ( mPRs). This dual activation initiates the genomic signaling pathway for long-term cell differentiation and the non-genomic pathway for rapid cellular responses. This molecular action leads to the fundamental physiological effect of endometrial secretory transformation and the reduction of myometrial smooth muscle contractility.


Neurosteroid Modulation of CNS Signaling

A critical systemic effect is mediated by the molecule's metabolite, Allopregnanolone, which acts as a neurosteroid. This metabolite functions as a positive allosteric modulator of the inhibitory GABA-A Receptors in the central nervous system ( CNS). By enhancing GABA's signaling, the mechanism increases inhibitory tone, resulting in decreased neuronal excitability and contributing to the molecule's established CNS effects.


Anti-Mineralocorticoid Activity

Ипрожин also engages in a competitive interaction at the Mineralocorticoid Receptors ( MRs). By acting as an antagonist against aldosterone at this site, the drug interferes with the signaling cascade responsible for sodium retention. This secondary mechanism primarily affects fluid and electrolyte homeostasis, promoting natriuresis (sodium and water excretion) as a resulting physiological consequence.

Dosage and Administration Information

How to Use Ипрожин (Micronized Progesterone)

The usage of Ипрожин, which contains micronized progesterone, is highly structured and determined by the administration route and the specific regimen determined by prescribing parameters. The medication is available in capsule form for oral or vaginal use, and as a solution for Intramuscular (IM) injection.

Dosing and Administration Schedules

The most common patterns involve cyclic, time-bound courses rather than continuous use, reflecting the hormone’s natural role. For secondary amenorrhea, a typical course involves taking the oral capsule at a 400 mg dose daily for 10 days. Conversely, for endometrial protection in combination with estrogen, the schedule is 200 mg taken daily for 12 consecutive days within a 28-day cycle. IM injection dosing is also time-limited, often prescribed at 5 mg to 10 mg daily for 6 to 8 consecutive days.

Administration Conditions and Constraints

To optimize systemic exposure, oral capsules are generally instructed to be taken with food, a condition that enhances the bioavailability of the micronized form. Instructions typically include taking the oral dose at bedtime (qHS) to mitigate potential systemic effects. Use in children is not established and is not recommended. Patients using the capsule form for the purpose of endometrial protection are required to use it in combination with an estrogen medicine, defining the context of administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ипрожин

This section provides an overview of the official scientific research and regulatory evidence that has examined progesterone, the active ingredient in Ипрожин. The focus is on the types of studies conducted, the outcomes they measured, and the limitations noted in the published scientific literature.


Evidence for Use in Assisted Reproductive Technology (ART) and Pregnancy Support

The role of progesterone in contexts of early pregnancy and fertility treatments was examined in numerous Randomized Controlled Trials (RCTs) and systematic reviews. The primary outcomes measured in these trials were related to reproductive metrics, such as the live birth rate and the ongoing pregnancy rate. For women undergoing ART, trials research describes patterns related to the use of progesterone as assessed by established markers of early pregnancy.

For conditions like recurrent pregnancy loss, findings were mixed across the total population studied, but research describes varying patterns of consistency in subgroups of women with three or more prior losses. It remains uncertain whether long-term outcomes are fully established, as follow-up in most studies was limited, focusing primarily on the first trimester of pregnancy.


Evidence for Protecting the Uterine Lining During Hormone Therapy

Progesterone was studied in the context of its use alongside estrogen as part of menopausal hormone therapy (MHT) in women with an intact uterus. This research was evaluated in large-scale observational cohort studies and RCTs.

The main focus of research was observed in outcomes related to uterine lining safety, primarily measuring the incidence of endometrial hyperplasia and evaluating endometrial histology. The evidence base data show patterns related to the use of progesterone that are consistent with the established outcomes monitored regarding the uterine lining. What remains uncertain is that there is limited information for long-term outcomes that extend beyond five years of continuous use.


Evidence for Regulating the Menstrual Cycle

The use of progesterone in studies of the menstrual cycle in women of reproductive age was evaluated in short-term, controlled trials and diagnostic studies. Primary outcomes monitored included the induction of withdrawal bleeding and the assessment of menstrual cycle regularity. Short-term trials research describes a high degree of consistency in the measured outcome of inducing withdrawal bleeding following a defined course of treatment in women with amenorrhea. However, there is limited information for long-term outcomes concerning cycle patterns over many years.

Key Studies & References

  1. Progesterone for Luteal Phase Support in Assisted Reproduction: A Systematic Review and Meta-analysis of Randomized Controlled Trials
  2. National Institute of Health (NIH) MedlinePlus Drug Information: Progesterone (Overview of studied uses)

Frequently Asked Questions (FAQ)

Common questions about Ипрожин (FAQ)

Q: What is the main difference between Ипрожин and other similar medicines?

A: Ипрожин is unique because its active component is micronized progesterone, which is chemically identical to the hormone produced naturally by the human body. This is a key difference when compared to other medicines in the same class, which contain synthetic progestins that have distinct chemical structures. Official documents describe this distinction, noting that synthetic versions may result in different profiles of effects.


Q: Why is my doctor asking me to take Ипрожин when I don't see this use listed everywhere?

A: According to official product information, this medicine is only approved for specific indications that are listed in regulatory documents. If a healthcare provider discusses uses or regimens that are not widely visible, it is generally recommended to communicate directly with them about the specific reasoning for your prescribed use.


Q: Can I take antacids or stomach medicines while using Ипрожин?

A: Official regulatory documents generally focus on strong drug interactions but do not typically list specific warnings for common antacids or stomach medicines. Official guidance suggests consultation with a healthcare professional or pharmacist to confirm compatibility with all concurrent over-the-counter medicines you may be using.


Q: Will Ипрожин show up on any standard lab tests?

A: Yes, because this medicine introduces high levels of the hormone into your body, it can significantly increase the concentration of progesterone found in the blood. This elevated level may influence the results or interpretation of a blood test specifically designed to measure your body’s naturally produced progesterone.


Q: Does İпрожин affect sleep quality?

A: Official safety information indicates that the oral form of this medicine is commonly associated with side effects such as somnolence (drowsiness) and dizziness. These effects are often tied to the medication's mechanism in the central nervous system and may affect a patient's state of wakefulness or sleep.


Q: Are there different doses of Ипрожин, and what do they mean?

A: Yes, official prescribing information defines different doses, such as 200 mg and 400 mg capsules. These various dose strengths are used by healthcare professionals to treat different regulatory-approved indications, such as endometrial protection or the treatment of secondary amenorrhea, as outlined in official documents.


Q: Can I take pain relievers like ibuprofen or paracetamol while using Ипрожин?

A: Official drug labels do not typically list specific warnings for common over-the-counter pain relievers such as ibuprofen or paracetamol. As with all treatments, official guidance recommends consultation with a healthcare professional or pharmacist to review all concurrent over-the-counter medicines you take.


Q: What should I do if the expected effect of Ипрожин doesn't happen?

A: According to general patient counseling guidelines, if the intended outcome of a medical treatment is not occurring as expected, official guidelines recommend consultation directly with the prescribing healthcare professional. They can discuss the status of the therapy and any necessary next steps.


Q: Why do some people use Ипрожин if they are not pregnant?

A: Official indications for this medicine include uses outside of pregnancy. These uses include the prevention of endometrial thickening in women undergoing Hormone Replacement Therapy (HRT) and the treatment of secondary amenorrhea, which is the absence of a menstrual period.


Q: How long does it usually take to notice the effects of Ипрожин?

A: While peak blood concentration is achieved within the first few hours after taking the oral dose, the observed clinical effects are tied to the completion of the specific, time-bound treatment courses defined in the regulatory regimen. Therefore, the effect is often related to the end of the course rather than an immediate change.


Q: Does Ипрожин cause weight gain for most people?

A: Regulatory documentation lists weight gain as a possible adverse reaction associated with the use of progestogens. Official safety information generally categorizes this as a less frequent or common side effect reported in clinical use.


Q: Can İпрожин affect my mood or emotions?

A: Yes, official regulatory safety documentation lists several potential adverse reactions related to emotional state. These include reported instances of mood changes, irritability, anxiety, tension, and depressed mood during clinical use of the medicine.


Q: What happens if I forget to take a dose of Ипрожин?

A: Official regulatory guidance generally states that patients should consult their prescribing information for specific directions regarding a missed dose. If a dose is missed, patients are generally advised to take it as soon as possible, or to skip it and resume the regular schedule. The guidance consistently advises against doubling doses to compensate for a forgotten one.


Q: Does the form of Ипрожин (e.g., capsule) affect how quickly it works?

A: Yes, the specific form of the medicine used significantly affects how the body processes it. Pharmacokinetic data indicates that the rate of absorption and clearance is different between the oral, vaginal, and intramuscular (IM) administration routes, which impacts the blood levels over time.


Q: Can men use Ипрожин for any reason?

A: The official indications for this medicine are exclusively established for adult women for reproductive and hormonal support purposes. Use in men is not an approved indication by regulatory bodies, though the medicine may be the subject of research studies in other populations.


Q: Is Ипрожин ever used in combination with fertility treatments?

A: Yes, the medicine is officially approved in many regions for use in Luteal Phase Support. This is a specific application of the drug used as part of Assisted Reproductive Technology (ART) procedures, as described in regulatory documentation.


Q: Is there a time limit on how long a person can safely use Ипрожин?

A: Regulatory approvals and clinical evidence for this medicine are typically limited to the specific durations defined by the approved indication (e.g., short, time-bound courses). Official documents often note that there is limited information for long-term outcomes that extend beyond these defined study periods.


Q: Do other medicines, like antibiotics, reduce the effectiveness of Ипрожин?

A: Certain medicines that are known as strong CYP3A4 inducers are documented to decrease the level and effect of progesterone by accelerating its clearance in the body. While specific antibiotics are not named as a class, if a medicine falls into this inducer category, it may reduce the effectiveness. Official guidance recommends consultation regarding all concurrent medicines.


Q: Are there any warnings about combining Ипрожин with herbal remedies?

A: Official regulatory documents specifically identify the herbal remedy St. John’s wort as a strong CYP3A4 inducer. It is documented that combining it with this medicine may decrease the level and effect of progesterone. Official guidance recommends consultation with a healthcare professional regarding all other herbal remedies.


Q: Can İпрожин be used by people with a history of depression?

A: Official regulatory documents state that the medicine is classified as requiring close medical supervision and caution for patients who have a history of depression. This means the healthcare provider will monitor the patient closely during the course of treatment.


Q: How does the use of Ипрожин compare between younger and older patients?

A: Use is generally not recommended in children and adolescents. Furthermore, official safety information indicates that for older adults (aged 65 and over), there is a documented increased risk of probable dementia reported when the drug is used in combination with estrogen therapy.


Q: Can İпрожин cause changes to the skin or hair?

A: Regulatory documents for this class of medicine have associated its use with certain adverse reactions related to the skin and hair. These can include effects such as acne and, less frequently, changes in hair growth or loss, as documented in safety information.


Q: Why is İпрожин sometimes prescribed to be taken before bed?

A: Official prescribing information advises taking the oral dose at bedtime (qHS) primarily to mitigate the potential systemic effects of the medicine. These effects include the common side effects of somnolence (drowsiness) and dizziness, which can be less disruptive if the medication is taken before sleep.


Q: If a person has high blood pressure, is Ипрожин still an option?

A: Official regulatory documents often indicate that a history of hypertension (high blood pressure) requires caution and close monitoring. This is due to the drug’s potential secondary effect on fluid and electrolyte homeostasis, a process related to the balance of water and salt in the body.

How should Ипрожин be stored and disposed of?

Official Storage and Disposal Instructions

Regulatory documents mandate specific storage conditions for this medication:

Storage Requirement Official Condition
Temperature Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F). Do not refrigerate or freeze.
Protection Must be protected from light and stored in the original outer carton or a light-resistant container.
Container Capsules must be kept in the original packaging. Injection vials must be stored upright.
Child Safety Keep out of the sight and reach of children.

Disposal of unused or expired product must be done strictly in accordance with local regulations. Used injection devices and associated sharps must be discarded immediately in an approved sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ипрожин found in:

A-Z Index: